Trial · NCT03508453
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neurofilament (biomarker) | 12 weeks | Treatment-related change in concentration of neurofilament (picograms per milliliter) |
| Primary | Urinary p75 neurotrophin receptor (biomarker) | 12 weeks | Treatment-related change in concentration of urinary p75 neurotrophin receptor (nanograms per milligram creatinine) |
| Primary | Monocyte CD14 receptor occupancy | 12 weeks | Treatment-related change in percent monocyte receptor occupancy |
| Secondary | Functional status | 12 weeks | Treatment-related change in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale \[0 (worst) to 48 (best)\] |
| Secondary | Respiratory function | 12 weeks | Treatment-related change in percent normal Forced Vital Capacity \[0% (worst) to 100%(best)\] |
| Secondary | Muscle function | 12 weeks | Treatment-related change in percent normal Sniff Nasal Pressure \[0% (worst) to 100% (best)\] |
| Secondary | Quality of life measured by ALSSQOL | 12 weeks | Treatment-related change in Amyotrophic Lateral Sclerosis Specific Quality of Life - Revised questionnaire \[0 (worst) to 460 (best)\] |
| Secondary | Cognitive and behavioural assessment | 12 weeks | Treatment-related change in Edinburgh Cognitive and Behavioural Assessment Score \[0(worst) to 136 (best)\] |
| Secondary | Maximum plasma concentration (Cmax) | 12 weeks | Maximum serum IC14 concentration (micrograms per milliliter) |
| Secondary | Area under the curve | 12 weeks | Area under the curve for serum IC14 (microgram x hr/mL) |
| Secondary | Immunogenicity | 16 weeks | Development of human anti-monoclonal antibodies following treatment |
| Secondary | Adverse events (safety, tolerability) | 16 weeks | Incidence of treatment-emergent adverse events (safety, tolerability) classified by MedDRA |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03508453/registered